Chen PJ, Hussmann JA, Yan J, et al. Enhanced prime editing systems by manipulating cellular determinants of editing outcomes. Cell. 2021;184(22):5635-5652.e29. doi:10.1016/j.cell.2021.09.018.

Vazquez F, Sellers WR. Are CRISPR Screens Providing the Next Generation of Therapeutic Targets?. Cancer Res. 2021;81(23):5806-5809. doi:10.1158/0008-5472.CAN-21-1784.

Nishimasu H, Shi X, Ishiguro S, et al. Engineered CRISPR-Cas9 nuclease with expanded targeting space. Science. 2018;361(6408):1259-1262. doi:10.1126/science.aas9129.

Sharifnia T, Hong AL, Painter CA, Boehm JS. Emerging Opportunities for Target Discovery in Rare Cancers. Cell Chem Biol. 2017;24(9):1075-1091. doi:10.1016/j.chembiol.2017.08.002.

Huang X, Zhou G, Wu W, et al. Genome editing abrogates angiogenesis in vivo. Nat Commun. 2017;8(1):112. doi:10.1038/s41467-017-00140-3.

Simeonov DR, Gowen BG, Boontanrart M, et al. Discovery of stimulation-responsive immune enhancers with CRISPR activation. Nature. 2017;549(7670):111-115. doi:10.1038/nature23875.

Flavahan WA, Drier Y, Johnstone SE, et al. Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs. Nature. 2019;575(7781):229-233. doi:10.1038/s41586-019-1668-3.

Lareau CA, Clement K, Hsu JY, et al. Response to "Unexpected mutations after CRISPR-Cas9 editing in vivo". Nat Methods. 2018;15(4):238-239. doi:10.1038/nmeth.4541.

Goldstein JT, Berger AC, Shih J, et al. Genomic Activation of PPARG Reveals a Candidate Therapeutic Axis in Bladder Cancer. Cancer Res. 2017;77(24):6987-6998. doi:10.1158/0008-5472.CAN-17-1701.

Pan J, Meyers RM, Michel BC, et al. Interrogation of Mammalian Protein Complex Structure, Function, and Membership Using Genome-Scale Fitness Screens. Cell Syst. 2018;6(5):555-568.e7. doi:10.1016/j.cels.2018.04.011.